Skip to main content

New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle

Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.